Connect with us

Hi, what are you looking for?


Britain Reclassifies CBD Oil as Medicine, While America Throws It in With Heroin

Photo by Getty Images

While the DEA has been busy reclassifying cannabidiol (CBD) as a Schedule I drug—right up there with heroin—our friends across the pond are rightly classifying it as a medicine.

The decision made on Monday by Britain’s Medicines & Healthcare products Regulatory Agency (MHRA) was based on credible claims that CBD successfully treats serious diseases.

The new classification means products containing CBD can now be legally distributed across the United Kingdom.

“We have come to the opinion that products containing cannabidiol (CBD) used for medical purposes are a medicine,” said an MHRA spokesperson on the agency’s website. “MHRA will now work with individual companies and trade bodies in relation to making sure products containing CBD, used for a medical purpose, which can be classified as medicines, satisfy the legal requirements of the Human Medicines Regulations 2012.”

Throughout 2016, an increasing number of British Parliament members called for reform of Britain’s “failing drug laws,” arguing that an evidence-based approach” should be central to effective drugs policies.

Thankfully, the government listened and acted accordingly.

Gerald Heddell, director of inspection and enforcement at MHRA, told Sky News: “The change really came about with us offering an opinion that CBD is in fact a medicine, and that opinion was based on the fact that we noted that people were making some quite stark claims about serious diseases that could be treated with CBD.”

This decision on the part of the MHRA comes only several months after the agency sent cease and desist orders to vendors and producers, ordering it to be “removed from sale in the UK.”

Although the UK does not recognize weed as having medical benefits, promoting the classification of CBD as a medicine is a step in the right direction.

In view of the fact that UK-based GW Pharmaceuticals has made huge strides recently with its CBD-based Epidiolex for rare, treatment-resistant epilepsy, the MHRA’s decision makes perfect sense.

So, what are we waiting for here in the U.S.?

It is not like we haven’t been exposed to the information. Indeed, U.S. researchers, including the American Epilepsy Society, have encouraged and/or undertaken relevant research.

In early December, researchers from the University of Alabama found that CBD oil reduces both the frequency and severity of seizures in children and adults with with severe, intractable epilepsy. In two-thirds of the 81 participants, the severity was reduced by at least 50 percent.

You can keep up with all of HIGH TIMES’ marijuana news right here.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *


HT Newsletter

Subscribe for exclusive access to deals, free giveaways and more!

Thank you for subscribing.

Something went wrong.


You May Also Like


Attorney General William Barr issued a statement on Saturday that the DEA would be “deployed to support local efforts to enforce federal law.”


A cannabis lobbying group is asking the DEA to leave cannabis research to health experts.


The move will make it easier for patients and caretakers to access the medication.


The DEA seems to be advancing plans to expand medical marijuana research.


This year, you can dispose of prescription drugs and vaping products.


The Office of the Inspector General called out the DEA for its role in the opioid epidemic.


The DEA needs more growers to assist in cannabis research.


UC Davis is teaming up with Biopharmaceutical Research Company.

Do NOT follow this link or you will be banned from the site!